TY - JOUR
T1 - Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population
AU - Törüner, Gökçe A.
AU - Akyerli, Cemaliye
AU - Uçar, Ahmet
AU - AkI, Tuncay
AU - Atsu, Necmettin
AU - Özen, Haluk
AU - Tez, Mesut
AU - Çetinkaya, Mesut
AU - Özçelik, Tayfun
N1 - Funding Information:
Acknowledgements The authors gratefully acknowledge grant support from the Turkish Scientific and Technical Research Association (TÜBI_TAK – SBAG 1948) and Bilkent University Research Fund, and the patient sample contributions from Drs. Mehmet Öztürk and IsË õk G.YulugÆ . We also thank Dr. Attila Halil Elhan for help in statistical analyses. All experiments were performed in accordance with Turkish law and regulations.
PY - 2001
Y1 - 2001
N2 - We investigated the effect of the GSTM1 and GSTT1 null genotypes, and GSTP1 313 A/G polymorphism on bladder cancer susceptibility in a case control study of 121 bladder cancer patients, and 121 age- and sex-matched controls of the Turkish population. The adjusted odds ratio for age, sex, and smoking status is 1.94 [95% confidence intervals (CI) 1.15-3.26] for the GSTM1 null genotype, and 1.75 (95% CI 1.03-2.99) for the GSTP1 313 A/G or G/G genotypes. GSTT1 was shown not to be associated with bladder cancer. Combination of the two high-risk genotypes, GSTM1 null and GSTP1 313 A/G or G/G, revealed that the risk increases to 3.91-fold (95% CI 1.88-8.13) compared with the combination of the low-risk genotypes of these loci. In individuals with the combined risk factors of cigarette smoking and the GSTM1 null genotype, the risk of bladder cancer is 2.81 times (95% CI 1.23-6.35) that of persons who both carry the GSTMl-present genotype and do not smoke. Similarly, the risk is 2.38-fold (95% CI 1.12-4.95) for the combined GSTP1 313 A/G and G/G genotypes and smoking. These findings support the role for the GSTM1 null and the GSTP1 313 AG or GG genotypes in the development of bladder cancer. Furthermore, gene-gene (GSTM1-GSTP1) and gene-environment (GSTMl-smoking, GSTP1-smoking) interactions increase this risk substantially.
AB - We investigated the effect of the GSTM1 and GSTT1 null genotypes, and GSTP1 313 A/G polymorphism on bladder cancer susceptibility in a case control study of 121 bladder cancer patients, and 121 age- and sex-matched controls of the Turkish population. The adjusted odds ratio for age, sex, and smoking status is 1.94 [95% confidence intervals (CI) 1.15-3.26] for the GSTM1 null genotype, and 1.75 (95% CI 1.03-2.99) for the GSTP1 313 A/G or G/G genotypes. GSTT1 was shown not to be associated with bladder cancer. Combination of the two high-risk genotypes, GSTM1 null and GSTP1 313 A/G or G/G, revealed that the risk increases to 3.91-fold (95% CI 1.88-8.13) compared with the combination of the low-risk genotypes of these loci. In individuals with the combined risk factors of cigarette smoking and the GSTM1 null genotype, the risk of bladder cancer is 2.81 times (95% CI 1.23-6.35) that of persons who both carry the GSTMl-present genotype and do not smoke. Similarly, the risk is 2.38-fold (95% CI 1.12-4.95) for the combined GSTP1 313 A/G and G/G genotypes and smoking. These findings support the role for the GSTM1 null and the GSTP1 313 AG or GG genotypes in the development of bladder cancer. Furthermore, gene-gene (GSTM1-GSTP1) and gene-environment (GSTMl-smoking, GSTP1-smoking) interactions increase this risk substantially.
KW - Bladder cancer
KW - Gene polymorphism
KW - Glutathione transferase
UR - http://www.scopus.com/inward/record.url?scp=0034766048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034766048&partnerID=8YFLogxK
U2 - 10.1007/s002040100268
DO - 10.1007/s002040100268
M3 - Article
C2 - 11757669
AN - SCOPUS:0034766048
SN - 0340-5761
VL - 75
SP - 459
EP - 464
JO - Archives of Toxicology
JF - Archives of Toxicology
IS - 8
ER -